摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(3-((4-bromobenzyl)oxy)phenyl)ethanone | 694446-91-8

中文名称
——
中文别名
——
英文名称
1-(3-((4-bromobenzyl)oxy)phenyl)ethanone
英文别名
1-[3-[(4-Bromophenyl)methoxy]phenyl]ethanone
1-(3-((4-bromobenzyl)oxy)phenyl)ethanone化学式
CAS
694446-91-8
化学式
C15H13BrO2
mdl
MFCD03999534
分子量
305.171
InChiKey
GSPANHMBPVYNMN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.133
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(3-((4-bromobenzyl)oxy)phenyl)ethanonepotassium carbonatecopper(ll) bromide 作用下, 以 氯仿乙酸乙酯N,N-二甲基甲酰胺 为溶剂, 反应 7.0h, 生成 1‑[3‑[(4‑bromobenzyl)oxy]phenyl]2‑(1H‑imidazol‑1‑yl)ethanone
    参考文献:
    名称:
    New Arylethanolimidazole Derivatives as HO-1 Inhibitors with Cytotoxicity against MCF-7 Breast Cancer Cells
    摘要:
    在这篇论文中,报道了一系列新型的咪唑基血红素氧合酶-1(HO-1)抑制剂。这些化合物是通过对先前描述的高效和选择性芳基乙醇咪唑进行修改而获得的。特别是,对中心连接物的简化和疏水部分的重新定位进行了。结果表明,中心区域的羟基对于药效以及疏水部分的空间分布至关重要。对接研究揭示了经典HO-1抑制剂与蛋白质活性位点的类似相互作用。最有效和选择性的化合物(5a)被测试其对激素敏感和激素抵抗性乳腺癌细胞系(MCF-7和MDA-MB-231)的潜在细胞毒活性。
    DOI:
    10.3390/ijms21061923
  • 作为产物:
    描述:
    3-羟基苯乙酮对溴溴苄potassium carbonate 作用下, 以 乙腈 为溶剂, 反应 8.0h, 以90%的产率得到1-(3-((4-bromobenzyl)oxy)phenyl)ethanone
    参考文献:
    名称:
    苄氧基取代的小分子单胺氧化酶B抑制剂对帕金森氏病的神经保护作用
    摘要:
    苄氧基取代的小分子是众所周知的高效单胺氧化酶B抑制剂,但尚未详细研究其对帕金森氏病的治疗潜力。在本文中,合成了一系列代表性的苄氧基取代的衍生物,并评估了对MAO-A / B的抑制作用。此外,在6-OHDA和鱼藤酮处理的PC12细胞中研究了它们的神经保护作用。观察到,大多数化合物在用神经毒素处理的PC12细胞的存活率中显示出明显的增加。其中,有13种表现出显着且平衡的神经保护效能。流式细胞术和染色方法证实了13对神经毒素诱导的细胞凋亡的保护作用。此外,根据体外BBB预测和体内急性毒性试验,13还显示出良好的BBB通透性和低毒性。结果表明13是有效和有希望的候选者,可以进一步开发作为帕金森氏病治疗的疾病缓解药物。
    DOI:
    10.1016/j.bmc.2016.09.050
点击查看最新优质反应信息

文献信息

  • Design, Synthesis, Biological Evaluation and Inhibition Mechanism of 3-/4-Alkoxy Phenylethylidenethiosemicarbazides as New, Potent and Safe Tyrosinase Inhibitors
    作者:Senchuan Song、Yuliang Mai、Huahong Shi、Bing Liao、Fei Wang
    DOI:10.1248/cpb.c19-00949
    日期:2020.4.1
    Tyrosinase plays important roles in many different disease related processes, and the development of its inhibitors is particularly important in biotechnology. In this study, thirty-nine 3-/4-alkoxyphenylethylidenethiosemicarbazides were synthesized as novel tyrosinase inhibitors based on structure-based molecular design. Our experimental results demonstrated that thirty-one of them possess remarkable tyrosinase inhibitory activities with IC50 value below 1 µM, and 5a, 6e, 6g and 6t did not display any toxicity to 293T cell line at the concentration of 1000 µmol/L. According to the inhibitory activities, several compounds were selected for detail investigation on the structure–activity relationships (SARs), mechanisms of enzyme inhibition, inhibitory kinetics and cytotoxicity. In particular, the interaction between the selected inhibitors and the active center of tyrosinase was considered and discussed in detail based on their structural characteristics. Taken together, the results presented here demonstrated that the newly designed compounds are promising candidates for the treatment of tyrosinase-related disorders and further development of them may have significant contribution in biomedical science.
    酪氨酸酶在多种与疾病相关的过程中扮演重要角色,其抑制剂的研发在生物技术领域尤为重要。本研究基于结构导向的分子设计,合成了39种新颖的3-/4-烷氧基苯乙烯基二唑半卡巴唑类化合物作为酪氨酸酶抑制剂。我们的实验结果显示,其中31种化合物的酪氨酸酶抑制活性显著,IC50值低于1µM,且5a、6e、6g和6t在1000µmol/L浓度下对293T细胞系无毒性。根据抑制活性,选取了若干化合物详细研究了构效关系、酶抑制机制、抑制动力学及细胞毒性。特别是,基于这些化合物的结构特征,详细考虑并讨论了所选抑制剂与酪氨酸酶活性中心的相互作用。综上所述,本研究结果表明,新设计的化合物是治疗与酪氨酸酶相关疾病的潜在候选药物,其进一步开发可能对生物医学科学产生重大贡献。
  • Acetophenone derivatives: novel and potent small molecule inhibitors of monoamine oxidase B
    作者:Zhi-Min Wang、Xue-Mei Li、Wei Xu、Fan Li、Jin Wang、Ling-Yi Kong、Xiao-Bing Wang
    DOI:10.1039/c5md00357a
    日期:——
    series of acetophenone derivatives have been designed, synthesized and evaluated for human monoamine oxidase A and B inhibitory activity in vitro. Most of the tested compounds acted preferentially on MAO-B with IC50 values in the nanomolar range and weak or no inhibition of MAO-A. In particular, compounds 1j (IC50 = 12.9 nM) and 2e (IC50 = 11.7 nM) were the most potent MAO-B inhibitors being 2.76- and 2
    已经设计,合成和评估了两个系列的苯乙酮衍生物在体外对人单胺氧化酶A和B的抑制活性。大多数测试的化合物优先以30纳摩尔范围的IC 50值对MAO-B起作用,对MAO-A的抑制作用弱或无抑制作用。特别是化合物1j(IC 50 = 12.9 nM)和2e(IC 50= 11.7 nM)是最有效的MAO-B抑制剂,其活性比司来吉兰高2.76倍和2.99倍。此外,MAO-B抑制的结构-活性关系表明,苯乙酮部分C3和C4处的取代基,特别是被卤素取代的苄氧基取代,对MAO-B抑制更有利。已经进行了分子对接和动力学研究以解释MAO-B与苯乙酮衍生物的结合模式。此外,代表性化合物1j和2e在SH-SY5Y细胞中显示出低神经毒性。可以得出结论,苯乙酮衍生物可用于开发有望用于治疗神经退行性疾病的先导化合物。
  • [EN] INHIBITORS OF HIV REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIH
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2011143772A9
    公开(公告)日:2012-12-20
  • New Arylethanolimidazole Derivatives as HO-1 Inhibitors with Cytotoxicity against MCF-7 Breast Cancer Cells
    作者:Valeria Ciaffaglione、Sebastiano Intagliata、Valeria Pittalà、Agostino Marrazzo、Valeria Sorrenti、Luca Vanella、Antonio Rescifina、Giuseppe Floresta、Ameera Sultan、Khaled Greish、Loredana Salerno
    DOI:10.3390/ijms21061923
    日期:——

    In this paper, a novel series of imidazole-based heme oxygenase-1 (HO-1) inhibitors is reported. These compounds were obtained by modifications of previously described high potent and selective arylethanolimidazoles. In particular, simplification of the central linker and repositioning of the hydrophobic portion were carried out. Results indicate that a hydroxyl group in the central region is crucial for the potency as well as the spatial distribution of the hydrophobic portion. Docking studies revealed a similar interaction of the classical HO-1 inhibitors with the active site of the protein. The most potent and selective compound (5a) was tested for its potential cytotoxic activity against hormone-sensitive and hormone-resistant breast cancer cell lines (MCF-7 and MDA-MB-231).

    在这篇论文中,报道了一系列新型的咪唑基血红素氧合酶-1(HO-1)抑制剂。这些化合物是通过对先前描述的高效和选择性芳基乙醇咪唑进行修改而获得的。特别是,对中心连接物的简化和疏水部分的重新定位进行了。结果表明,中心区域的羟基对于药效以及疏水部分的空间分布至关重要。对接研究揭示了经典HO-1抑制剂与蛋白质活性位点的类似相互作用。最有效和选择性的化合物(5a)被测试其对激素敏感和激素抵抗性乳腺癌细胞系(MCF-7和MDA-MB-231)的潜在细胞毒活性。
  • Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson’s disease
    作者:Zhimin Wang、Jiajia Wu、Xuelian Yang、Pei Cai、Qiaohong Liu、Kelvin D.G. Wang、Lingyi Kong、Xiaobing Wang
    DOI:10.1016/j.bmc.2016.09.050
    日期:2016.11
    The benzyloxy substituted small molecules are well-known highly potent monoamine oxidase B inhibitors, but their therapeutic potential against Parkinson’s disease have not been investigated in detail. In this paper, a series of representative benzyloxy substituted derivatives were synthesized and evaluated for MAO-A/B inhibition. In addition, their neuroprotective effects were investigated in 6-OHDA-
    苄氧基取代的小分子是众所周知的高效单胺氧化酶B抑制剂,但尚未详细研究其对帕金森氏病的治疗潜力。在本文中,合成了一系列代表性的苄氧基取代的衍生物,并评估了对MAO-A / B的抑制作用。此外,在6-OHDA和鱼藤酮处理的PC12细胞中研究了它们的神经保护作用。观察到,大多数化合物在用神经毒素处理的PC12细胞的存活率中显示出明显的增加。其中,有13种表现出显着且平衡的神经保护效能。流式细胞术和染色方法证实了13对神经毒素诱导的细胞凋亡的保护作用。此外,根据体外BBB预测和体内急性毒性试验,13还显示出良好的BBB通透性和低毒性。结果表明13是有效和有希望的候选者,可以进一步开发作为帕金森氏病治疗的疾病缓解药物。
查看更多